The ‘BPCIA’ the U.S. plays the worst policy to the Korean biosimilarindustry
Facing enforcement ofthe Korea-US FTA’s (Free Trade Agreement) Patent Linkage System within a month, needs of active responses of biosimilar manufacturers and the government have been suggested.
The political and systematical issues of global and domestic biosimilarsare recognition on acceptance...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
